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Effects of n-3 Polyunsaturated Fatty Acids
on Left Ventricular Function and Functional
Capacity in Patients With Dilated Cardiomyopathy
Savina Nodari, MD,* Marco Triggiani, MD,* Umberto Campia, MD,‡ Alessandra Manerba, MD,*
Giuseppe Milesi, MD,* Bruno M. Cesana, MD,† Mihai Gheorghiade, MD,‡ Livio Dei Cas, MD*
Brescia, Italy; and Chicago, Illinois
Objectives This study was designed to test the effects of n-3 polyunsaturated fatty acids (PUFAs) on left ventricular (LV)
systolic function in chronic heart failure (HF) due to nonischemic dilated cardiomyopathy (NICM).
Background One hundred thirty-three patients with NICM and minimal symptoms on standard therapy were randomized to
2 g of n-3 PUFAs or placebo. LV function and functional capacity were assessed prospectively by echocardiogra-
phy and cardiopulmonary exercise testing at baseline and at 12 months after randomization.
Methods Patients with chronic HF due to NICM and minimal symptoms while receiving evidence-based therapy were en-
rolled. LV function and functional capacity were assessed prospectively by echocardiography, cardiopulmonary
exercise test, and New York Heart Association functional class at baseline and at 12 months after randomiza-
tion to either 2 g of n-3 PUFAs or placebo.
Results At 12 months after randomization, the n-3 PUFAs group and the placebo group differed significantly (p 0.001)
in regard to: 1) LV ejection fraction (increased by 10.4% and decreased by 5.0%, respectively); 2) peak VO2 (in-
creased by 6.2% and decreased by 4.5%, respectively); 3) exercise duration (increased by 7.5% and decreased
by 4.8%, respectively); and 4) mean New York Heart Association functional class (decreased from 1.88  0.33
to 1.61  0.49 and increased from 1.83  0.38 to 2.14  0.65, respectively). The hospitalization rates for HF
were 6% in the n-3 PUFAs and 30% in the placebo group (p  0.0002).
Conclusions In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treat-
ment increases LV systolic function and functional capacity and may reduce hospitalizations for HF. Given these
promising results, larger studies are in order to confirm our findings. (J Am Coll Cardiol 2011;57:870–9)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.017Despite the improvement in morbidity and mortality
achieved with the use of current treatments, heart failure
(HF) is still associated with an overall poor prognosis and
with high hospitalization rates (1). The results of the
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venza nell’Infarto Miocardico–Heart Failure) trial indicate
that in patients with chronic HF receiving evidence-based
medical therapy and in New York Heart Association
(NYHA) functional class II to IV, long-term treatment
with n-3 polyunsaturated fatty acids (PUFAs) 1 g daily
reduces mortality and hospitalizations for cardiovascular
reasons, irrespective of etiology and left ventricular (LV)
ejection fraction (EF) (2).
See page 880
Several potential mechanisms may underlie the beneficial
effects of n-3 PUFAs in HF patients, including, but not
limited to, antiarrhythmic and hemodynamic actions. In
particular, experimental and clinical studies have shown that
n-3 PUFAs may ameliorate endothelial function (3), blood
pressure and heart rate (4), and arterial compliance (5).
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February 15, 2011:870–9 PUFAs in Heart FailureFurthermore, in an animal model of HF, treatment with
dietary eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) prevents the increase in LV end-diastolic and end-
systolic volumes and the shift between alfa- and beta-myosin
chains secondary to aortic banding (6). However, whether n-3
PUFAs may improve LV function in patients with HF
remains unknown. The current investigation was therefore
designed to test the hypothesis that treatment with n-3 PUFAs
improves LV systolic function expressed as EF in patients with
stable chronic HF secondary to a nonischemic dilated cardio-
myopathy (NICM). Additionally, we sought to determine
whether n-3 PUFAs also exert positive effects on LV diastolic
function assessed by echocardiography, functional capacity
expressed as peak VO2 assessed by cardiopulmonary stress
esting (CPET), and NYHA functional class.
ethods
atient population. Patients aged between 18 and 75 years
ith a diagnosis of NICM, LV systolic dysfunction (defined as
n EF 45%), and stable clinical conditions with minimal or
o symptoms for at least 3 months on evidence-based medical
reatment at maximum tolerated target doses for at least 6
onths were considered eligible for the study. In all patients,
he diagnosis of NICM was based on the absence of stenoses
50% on coronary artery angiography performed at the time
f the workup of the cardiomyopathy. Furthermore, additional
maging tests had been performed in the presence of subse-
uent changes in clinical status or if symptoms suggestive of
schemia had occurred. The following criteria were grounds for
xclusion: presence of symptoms or evidence of coronary artery
isease diagnosed through noninvasive tests, peripheral arterial
isease, presence of congenital or primary valvular heart dis-
ase, persistent atrial fibrillation, inability to perform bicycle
rgometry for noncardiac causes, moderately to severely re-
uced functional capacity, NYHA functional class IV, poor
coustic windows limiting the ability to assess echocardio-
raphic measurements, chronic lung disease, advanced renal
isease (estimated glomerular filtration rate [eGFR] 30
l/min/1.73 m2), advanced liver disease; any disease limiting
ife expectancy to 1 year, contraindications to study drugs,
nd concomitant participation in other research studies.
xperimental design. The study had a double-blind,
lacebo-controlled, 2-arm design. Potential participants were
ecruited consecutively from the HF outpatient clinic of the
niversity of Brescia and were scheduled to undergo a screen-
ng visit including history and physical exam, electrocardio-
ram (ECG), blood draw for complete blood count and
hemistry panel for electrolytes and renal and liver function
ests, and echocardiogram with Doppler. Within 2 weeks after
he screening visit, all eligible patients underwent CPET,
hich was preceded by a training session to familiarize with the
quipment. Participants were subsequently randomized to
ither 1.0-g gelatin capsules containing 850 to 882 mg of EPA
nd DHA ethyl esters in the average ratio (EPA/DHA) of
.9:1.5 (OMACOR, Pronova Biopharma, Lysaker, Norway)r to 1.0-g gelatin capsules of pla-
ebo (olive oil) of identical appear-
nce. The treatment dose was 5
apsules daily for the first month
ollowed by 2 capsules daily for the
est of the study. Capsules were
ispensed on a monthly basis in a
lass bottle containing 80 capsules.
rug compliance was assessed by
ill count at each monthly visit.
atients were considered noncom-
liant and withdrawn from the
tudy if less than 80% of the ex-
ected number of capsules had
een taken. Follow-up visits were
cheduled at monthly intervals or
t any time clinical events consid-
red potentially significant by the
tudy physician were reported. At
he 12-month follow-up visit,
hysical exam, ECG, blood draw
or complete blood count and
hemistry panel including renal
nd liver function tests, echocar-
iogram with Doppler, and
PET were repeated. The study
rotocol was approved by the
nstitutional Review Board of the
niversity of Brescia (Brescia, It-
ly). The study complied with the
eclaration of Helsinki and the
uidelines for Good Clinical
ractice. A written informed con-
ent was obtained from each patient.
rocedures. ECHOCARDIOGRAPHIC EVALUATION. The
echocardiographic study, including 2-dimensional,
M-mode, and Doppler imaging, was performed using a
General Electric Vivid 7.0 (General Electric Healthcare,
Milan, Italy) with a 2.5-MHz transducer. The following
parameters were measured according to the professional
standards defined by the American Society of Echocardi-
ography and the European Association of Echocardiogra-
phy (7): LV end-diastolic and -systolic diameter and LV
end-diastolic and end-systolic volume; LVEF (%) calculated
by Simpson’s biplane method; shortening fraction (%);
degree of mitral regurgitation by Doppler and color Dopp-
ler, scored on a scale from 0 to 4 (0  none, 1  trace, 2 
mild, 3  moderate, and 4  severe); left atrial diameter;
LV posterior wall thickness and interventricular septal
thickness; right atrial pressure; pulmonary artery systolic
pressure; mitral diastolic inflow velocities (peak velocity of
early ventricular filling [E-wave], peak velocity of late
ventricular filling [A-wave], E/A ratio, and E-wave decel-
eration time); diastolic function score, graded on a scale
from 1 to 4 (normal, impaired relaxation, pseudonormal,
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme inhibitor
ARB  angiotensin II
receptor blocker
CPET  cardiopulmonary
stress testing
DHA  docosahexaenoic
acid
eGFR  estimated
glomerular filtration rate
ECG  electrocardiogram
EPA  eicosapentaenoic
acid
FFA  free fatty acid
HF  heart failure
HR  heart rate
IL  interleukin
LV  left ventricular
LVEF  left ventricular
ejection fraction
NICM  nonischemic
dilated cardiomyopathy
NYHA  New York Heart
Association
PUFA  polyunsaturated
fatty acid
TNF  tumor necrosis
factor
VO2  oxygen uptakeand restrictive), with higher scores indicating worse diastolic
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PUFAs in Heart Failure February 15, 2011:870–9function (8). Echocardiographic exams were performed by a
single cardiologist (G.M.) and interpreted by a different
cardiologist (A.M.), both blinded to patients’ treatment.
CARDIOPULMONARY EXERCISE TESTING. Bicycle ergome-
er CPET was performed by trained staff under the supervision
f 2 cardiologists; all patients were instructed and underwent a
raining session to familiarize with the equipment (Medical
raphics Italia, Milan, Italy). A light breakfast was allowed 2 h
efore the test. All tests were performed between 10 AM and 1
PM in a temperature-controlled room (21°C to 23°C), with
tandard 12-lead continuous ECG monitoring (Cardio Per-
ect, Medical Graphics Italia). Blood pressure was measured
anually. A ramp protocol at a pedal speed of 60 revs/min
ith a linear increase in workload at a rate of 1 W every 6 s
10 W/min) was used. All tests were interrupted for symptoms
dyspnea and/or fatigue). Minute ventilation, oxygen uptake
VO2), carbon dioxide output, and other cardiopulmonary
ariables were acquired breath-by-breath by pneumotacho-
raph with bidirectional differential pressure (preVent Pneu-
otach, Medical Graphics, St. Paul, Minnesota). Resting VO2
and heart rate (HR) were computed as the mean values
recorded during the last 30 s of the resting period, whereas
peak effort VO2 was calculated as the mean values during the
ast 30 s of effort. Automatic calculation of the anaerobic
hreshold was obtained by the Wassermann or V-slope
ethod (9). A CPET was considered adequate if the peak
espiratory exchange ratio was higher than 1.05. Maximum
R predicted for age was calculated as: (220 – age). The
ercentage of the peak HR in relation to the maximal HR
redicted for the age was calculated as: (peak HR/predicted
R)  100. The percentage of maximum predicted VO2 (%
VO2max) was calculated as the ratio between VO2peak and
theoretical VO2max, according to the standard formula: [([50.72
 (0.372 age)]  weight)/weight] for males and [([22.78
(0.17  age)]  (weight  43))/weight] for females
(10,11). CPET exams were performed and interpreted by 2
cardiologists (A.M. and G.M.) blinded to patients’
treatment.
LABORATORY EXAMS. Blood samples were collected for the
ssessment of complete blood count, comprehensive chem-
stry panel, inflammatory cytokines including tumor necro-
is factor (TNF)-alpha, interleukin (IL)-6 and IL-1, and
erum free fatty acids (FFAs). Inflammatory cytokine levels
ere measured using venous blood collected in empty tubes
nd centrifuged within 1 h at 1,700 rpm at 4°C for 15 min.
he collected serum was stored at –80°C for assessment by
mmunoenzymatic test with spectrophotometric determina-
ion (12). Plasma levels of n-3 and n-6 PUFAs were
easured on blood samples drawn after 10 h of fasting,
ollected in K3 ethylenediaminetetraacetic acid–containing
ubes, centrifuged at 400 rpm at 4°C for 10 min, and
ubsequently stored at 20°C. Plasma FFAs including
inoleic acid, arachidonic acid, alpha-linolenic acid, EPA,
nd DHA were analyzed by gas–liquid chromatography
fter derivation to methyl esters and expressed as percentagef total FFAs. Briefly, 50 l of plasma were directly
ethylated with 1 ml of 3 N MeOH/HCl (Supelco,
ellafonte, Pennsylvania). After 1 h of incubation at 90°C,
FAs were extracted twice with 2 ml of water, 2 ml of a
Cl-saturated solution, and 2 ml of n-hexane (13). The
esulting fatty acid methyl esters were separated by gas–
iquid chromatography (85.10; Dani Instruments S.p.a.,
ologno Monzese, Italy) equipped with a capillary column
Omegawax 320, Supelco), flame ionization detector, and
rogrammed temperature vaporizing injector. The interas-
ay coefficients of variation were 0.9% and 1.3% for EPA
nd DHA, respectively. The omega-3 index was calculated
rom (EPA  DHA) per total FFA content.
tatistical analysis. Continuous variables are expressed as
ean (SD). Categorical variables are presented as absolute
nd percent values and were compared by chi-square test.
nalysis of covariance on the value detected at the 12-
onth follow-up with baseline value of the main variables as
ovariate was not possible owing to the statistical signifi-
ance of the parallelism test. For each parameter, the
nalysis of the results was done following an intention-to-
reat approach by means of the unpaired Student t test or
ilcoxon rank sum test as appropriate on the differences
before minus after the treatment). In case of a statistically
ignificant interaction, within-group comparisons were car-
ied out by means of an “a posteriori” test with the
ignificance level reduced by means of the Bonferroni
orrection. Statistical significance was set at p  0.05
2-tailed).
The primary end point of the study was the change in
V systolic function expressed as LVEF between baseline
nd 12-month follow-up. Secondary end points included:
) change in LV diastolic function assessed by echocardi-
graphy; 2) change in functional capacity expressed as peak
O2; and 3) change in NYHA functional class between
baseline and 12-month follow-up.
Sample size calculation was based on the difference
between the change of LVEF in the treatment with n-3
PUFA 2 g daily in comparison with placebo. We hypoth-
esized that n-3 PUFA administration would be associated
with an improvement of effect size of 0.5 in LVEF (or 3%
for a phenomenon variability, difference between baseline
and 12-month follow-up of 6%). A sample of 65 patients in
each group was calculated to have 80% power to detect such
0.5 effect size with   0.05 (2-tailed) at the Student t test
for unpaired data. Analyses were performed using SAS
software (version 9.1, SAS Institute, Cary, North Carolina).
Results
The flow chart of the study is shown in Figure 1. A total of
133 patients took part in the study. The first patient was
enrolled on November 5, 2007, and the last patient com-
pleted the study on June 30, 2009. The mean age of the
study population was 63  10 years; 13 (9.8%) of the
participants were women; all patients were being treated
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February 15, 2011:870–9 PUFAs in Heart Failurewith an angiotensin-converting enzyme inhibitor (ACE-I)
or angiotensin II receptor blocker (ARB), a beta-blocker,
and furosemide, and 80 patients (60.2%) were also receiving
an aldosterone receptor blocker. In both arms, compliance
levels to study treatment were above 80%, and no patient
was withdrawn because of noncompliance. Baseline echo-
cardiographic findings confirmed the presence of LV en-
largement (mean LV end-diastolic diameter and LV end-
diastolic volume of 68  6 mm and 192  44 mL,
respectively) and moderate LV systolic dysfunction (mean
LVEF 37  6%). Cardiopulmonary exercise test showed a
mean peak VO2 of 19  4 mL/kg/min and a mean
ercentage of maximum predicted VO2 of 70  11%.
The baseline demographic and clinical characteristics
according to study groups are reported in Table 1.
Effects of treatments on circulating levels of n-3 PUFAs.
At baseline, EPA  DHA accounted for 1.68  0.43% and
1.76  0.50% of circulating FFAs in the placebo and in the
n-3 PUFAs group, respectively (p 0.363). At the 12-month
follow-up, no significant changes in EPADHA concentra-
tions were observed in the patients on placebo (1.66  0.41%
vs. 1.68 0.43%; p 0.082). In contrast, a significant increase
was observed in the patients treated with n-3 PUFAs (from
1.76 0.50% to 4.31 0.83%; p 0.001). Thus at the end
of the treatment period, n-3 PUFA levels were significantly
higher in the active treatment than in the placebo group
Figure 1 Flow Diagram of the Phases of the Study
The various phases of the study and the number of patients assessed for eligibilit
CPET  cardiopulmonary stress testing; PUFA  polyunsaturated fatty acid.(p  0.001). EEffects of n-3 PUFAs on ejection fraction and other
parameters of LV systolic function. In patients random-
ized to n-3 PUFAs, a significant increase in LVEF (10.4 
9.5%; p  0.001) was observed at the 12-month follow-up
compared with baseline. In contrast, a statistically signifi-
cant decrease of LVEF (5.0  3.8%; p  0.001) was
observed in the placebo group. The comparison of the
changes of LVEF from baseline to 12-month follow-up
between the 2 groups was statistically significant (p 
0.001) (Fig. 2) Treatment with n-3 PUFAs resulted in a
reduction of LV diameters (1.8%, p  0.0001; and
4.5%, p  0.001, for LV end-diastolic diameter and LV
end-systolic diameter, respectively) and LV volumes
(2.5%, p  0.001; and 7.5%, p  0.0001, for LV
end-diastolic volume and LV end-systolic volume, respec-
tively). In contrast, in the placebo group, small increases in
LV end-diastolic diameter (0.9%; p  0.001), LV end-
systolic diameter (0.86%; p  0.0001), and LV end-systolic
volume (1.03%; p  0.001), but not in LV end-diastolic
olume, were observed. The comparison of the changes in
V end-diastolic diameter, LV end-systolic diameter, LV
nd-diastolic volume, and LV end-systolic volume from
aseline to the 12-month follow-up between the 2 groups
as statistically significant (p  0.001 for all) (Table 2).
ffects of n-3 PUFAs on diastolic function. In the pa-
ients treated with n-3 PUFAs, at the 12-month follow-up, the
ally enrolled, and randomized are shown.y, actu-wave and A-wave velocities and the E/A ratio were similar
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PUFAs in Heart Failure February 15, 2011:870–9to baseline. However, the deceleration time was significantly
increased (12.1%; p 0.0001), and the diastolic function score
as significantly decreased (4.74%; p  0.004), suggesting
an improvement in diastolic function (Table 2). In the placebo
group, compared with baseline, an increase in the E-wave
velocity (12.5%; p 0.006) with a nonsignificant change in the
-wave velocity and E/A ratio (3.9%, p  0.77; and
14.9%, p  0.11, respectively) were observed at the 12-
onth follow-up. However, a decrease of the deceleration
ime (6.7%; p  0.001) and an increase of the diastolic
function score (10.1%; p  0.003) were recorded in these
patients, suggesting a worsening of diastolic function. The
comparison of the changes of E-wave velocity and the E/A
ratio from baseline to the 12-month follow-up between the
2 groups was statistically significant (p  0.023 and p 
0.038, respectively), whereas no significant difference in the
change of A-wave velocity was noted (p  0.714). At the
nd of the treatment period, the diastolic function score was
ignificantly lower in the n-3 PUFA group than in the
lacebo group (p  0.001) (Table 2). Compared with
aseline, at the 12-month follow-up, 80% of patients
eceiving placebo presented the same diastolic function
Baseline Demographic andClinical Characterist s of Study PatientsTable 1 Bas l ne Demographic andClinical Characteristics of Study Patients
Placebo
(n  66)
n-3 PUFAs
(n  67)
Age, yrs 64 9 61 11
Male 56 (84.9) 64 (95.5)
Weight, kg 76.0 7.5 76.9 10.1
BMI, kg/m2 25.7 2.22 25.9 2.3
Time since diagnosis, yrs 4.1 1.5 4.2 1.7
NYHA functional class
Average 1.83 0.38 1.88 0.33
Class I 11 (16.7) 8 (11.9)
Class II 55 (83.3) 59 (88.05)
Diabetes 15 (23) 7 (10.4)
SBP, mm Hg 120.5 12.2 119.5 9.2
DBP, mm Hg 76.2 5.1 76.0 5.2
HR, beats/min 62 4 62 5
Creatinine, mg/dl 1.13 0.23 1.10 0.21
eGFR, ml/min 75.7 27.5 81.4 26.9
ICD 26 (39.4) 27 (40.3)
CRT 22 (33.3) 17 (25.4)
Medications
ACE-I 59 (89.4) 52 (77.6)
ARBs 7 (10.6) 15 (22.4)
ACE-I/ARB 66 (100) 67 (100)
Aldosterone blockers 42 (63.6) 38 (56.7)
Beta-blockers 66 (100) 67 (100)
Amiodarone 35 (53) 27 (40.3)
Furosemide 66 (100) 67 (100)
Statins 11 (17) 7 (10)
Data are expressed as mean  SD or n (%).
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CRT 
cardiac resynchronization therapy; DBP  diastolic blood pressure; eGFR  estimated glomerular
filtration rate; HR  heart rate; ICD  implantable cardioverter-defibrillator; NYHA  New York
Heart Association; PUFA  polyunsaturated fatty acid; SBP  systolic blood pressure.core, whereas 18% had an increase and 2% had a decreasen this parameter. In the n-3 PUFA group, at the 12-month
ollow-up, 78% had no change in their baseline diastolic
unction score, whereas 19% had a reduction and 3% had an
ncrease from the baseline value. When compared between
roups, these changes were statistically significant (p 
.0002).
ffects of n-3 PUFAs on exercise capacity. In the placebo
roup, compared with baseline, a significant decrease of
eak VO2 (4.9%; p  0.001), percent of predicted peak
VO2 (2.9%; p  0.001), length of exercise (5.7%; p 
0.001), and workload (–5.3%; p  0.001) were observed at
the 12-month follow-up. In contrast, n-3 PUFA–treated
patients showed a significant increase in peak VO2 (6.2%;
 0.001), percent of predicted peak VO2 (4.3%; p 
0.001), length of exercise (7.7%; p  0.001), and workload
(7.1%; p  0.002). The comparison of the changes of these
parameters from baseline to the 12-month follow-up be-
tween the 2 groups was statistically significant (Table 3).
Effects of n-3 PUFAs on NYHA functional class. At the
end of treatment, among patients receiving placebo, 47
(71.2%) remained in the same NYHA functional class,
whereas 19 (28.8%) increased their NYHA functional class,
suggestive of worsening clinical status. In the n-3 PUFA
group, 49 patients (73.1%) maintained their initial NYHA
functional class, whereas 18 (26.9%) were assigned to a lower
NYHA functional class, indicating functional improvement.
No patients had an increase of their NYHA functional class
from baseline, suggesting that no patients experienced a func-
tional decline during follow-up. When compared between
groups, these changes were statistically significant (p  0.001)
(Fig. 3).
Effects of n-3 PUFAs on inflammatory cytokines and
other metabolic parameters. After 12 months of placebo,
levels of TNF-alpha, IL-6, and IL-1 were significantly
increased from baseline. In contrast, the concentrations of
Figure 2 Changes in Ejection Fraction in the Study Groups
Comparison is shown between the mean percent changes in ejection fraction
from baseline to 12-month follow-up recorded in the placebo and in the n-3
polyunsaturated fatty acids (PUFAs) group.
v ntricul
e pulmon
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February 15, 2011:870–9 PUFAs in Heart Failurethese inflammatory cytokines were significantly decreased at
the end of treatment with n-3 PUFAs. When compared
between groups, these changes were statistically significant
(p  0.001) (Table 4).
Both in the placebo and active treatment group, no signif-
icant changes were noted in glucose and total cholesterol
concentrations between baseline and the 12-month follow-up.
A borderline significant decrease in triglyceride levels was
observed in the n-3 PUFA–treated patients at the 12-month
follow-up compared with baseline. When compared between
groups, these changes were not significant (Table 4).
Predictors of changes in ejection fraction in n-3 PUFA–
treated patients. To explore possible predictors of the
response to active treatment, we performed univariate and
multivariate analyses between changes in EF and: 1) time
Echocardiographic Parameters at Baseline and at 12-Month FollowTable 2 Echocardiographic Parameters at Baseline and at 12-M
Variable
Placebo
Baseline 12 Months p Value
LVEDD, mm 67.9 4.5 68.4 4.5 0.001
LVESD, mm 53.9 6.5 54.3 6.4 0.001
LVFS, % 21 6 21 6 0.59
LVEDV, ml 193 26 194 26 0.69
LVESV, ml 123 25 124 26 0.001
LVEF, % 37 6 35 6 0.001
PWT, mm 8.8 1.0 8.8 0.9 0.59
IVST, mm 8.8 1.4 8.8 1.1 0.48
LA size, mm 45 5 45 5 0.97
DT, ms 217 38 200 33 0.001
DF score 2.17 0.48 2.32 0.47 0.03
PASP, mm Hg 29 9 33 7 0.001
MR score 1.71 0.49 1.83 0.57 0.09
E, cm/s 55 20 61 25 0.006
A, cm/s 65 19 66 18 0.77
E/A 0.90 0.37 0.98 0.40 0.11
Data are expressed as mean SD. *p values refer to the comparison of the changes in echocard
A  peak velocity of late ventricular filling; DF  diastolic function; DT  deceleration time; E
entricular end-diastolic diameter; LVESD  left ventricular end-systolic diameter; LVFS  left ve
nd-systolic volume; LVEF  left ventricular ejection fraction; MR  mitral regurgitation; PASP 
Cardiopulmonary Exercise Testing Parameters at Baseline and 12-MTable 3 Cardiopulmonary Exercise Testing Parameters at Base
Variable
Placebo
Baseline 12 Months p Va
Time, min 10.6 2.1 10.0 2.0 0.
Workload, W 114 31 108 30 0.
HR rest, beats/min 62 4 64 4 0.
HR max, beats/min 121 18 117 22 0.
% HR max 78 9 75 13 0.
Peak VO2, ml/kg/min 18.3 4.4 17.4 4.2 0.
% VO2 max 70 13 68 13 0.
Rest SBP, mm Hg 120 12 119 11 0.
Rest DBP, mm Hg 76 5 76 5 0.
Peak SBP, mm Hg 149 14 148 14 0.
Peak DBP, mm Hg 85 8 85 12 0.Data are expressed as mean SD. *p values refer to the comparison of the changes in cardiopulmonar
DBP  diastolic blood pressure; SBP  systolic blood pressure; VO2  oxygen uptake; other abbreviatfrom diagnosis of NICM; 2) baseline EF; and 3) the
baseline values of TNF-alpha, IL-6, and IL-1. On univar-
iate analysis, cytokine levels were directly correlated,
whereas time from diagnosis and baseline EF were inversely
correlated, with changes in EF. When fitted in a multivar-
iate model, only time from diagnosis and TNF-alpha
retained their significance (Table 5).
Events at follow-up. Treatment with n-3 PUFAs was well
tolerated. No serious adverse events were recorded in either
treatment group, and no patients discontinued treatment
throughout follow-up. No significant difference in all-cause
hospitalization was observed between the placebo- and n-3
PUFA–treated patients. However, a significantly lower
number of patients in the active treatment group required
hospitalization for cardiovascular causes and/or worsening
Follow-Up
n-3 PUFAs
p Value*Baseline 12 Months p Value
67.4 6.9 66.1 6.7 0.001 0.001
52.8 7.4 50.4 7.0 0.001 0.001
22 6 24 6 0.001 0.001
191 56 186 53 0.001 0.001
123 40 113 35 0.001 0.001
36 7 39 6 0.001 0.001
8.8 1.0 8.7 1.0 0.06 0.292
8.9 1.1 8.8 1.1 0.13 0.172
44 5 43 4 0.001 0.001
219 41 241 33 0.001 0.001
2.18 0.42 2.01 0.27 0.003 0.001
29 8 27 4 0.02 0.001
1.61 0.60 1.22 0.62 0.001 0.001
60 28 55 18 0.06 0.023
70 16 67 20 0.96 0.714
0.89 0.29 0.84 0.19 0.17 0.038
ic parameters observed in each group between baseline and 12-month follow-up.
locity of early ventricular filling; IVST interventricular septum thickness; LA left atrium; LVEDD left
ar fractional shortening; LVEDV  left ventricular end-diastolic volume; LVESV  left ventricular
ary artery systolic pressure; PUFA  polyunsaturated fatty acid; PWT  posterior wall thickness.
h Follow-Upnd 12-Month Follow-Up
n-3 PUFAs
p Value*Baseline 12 Months p Value
10.4 1.9 11.2 2.1 0.001 0.0013
113 30 121 32 0.002 0.001
62 4 60 3 0.001 0.001
122 17 125 22 0.046 0.005
77 7 79 10 0.047 0.006
19.5 3.8 20.7 4.3 0.001 0.001
0.70 0.09 0.73 0.09 0.001 0.0068
119 9 121 6 0.049 0.015
76 5 75 4 0.15 0.986
149 15 151 11 0.20 0.026
84 7 83 6 0.015 0.163-Uponth
iograph
peak veontline a
lue
001
001
001
04
04
001
001
13
07
02
67y stress testing parameters observed in each group between baseline and 12-month follow-up.
ions as in Table 1.
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PUFAs in Heart Failure February 15, 2011:870–9HF (Table 6). Among patients receiving placebo, implant-
able cardioverter-defibrillator interrogation showed the oc-
currence of 9 appropriate shocks during follow-up, whereas
in those receiving active treatment, only 2 events were
recorded. The difference in the number of shocks between
the 2 groups was statistically significant (p  0.026). In the
placebo group, 16 patients (24%) required an increase of
furosemide dosage and 50 patients (76%) maintained the
baseline dose, whereas among the n-3 PUFA–treated pa-
tients, the dose of furosemide was maintained in 41 patients
(61%) and reduced in 26 patients (39%). No increase of
diuretic dose was recorded in the n-3 PUFA group at the
12-month follow-up as compared with baseline. When
Figure 3 NYHA Functional Class
Distribution in the Study Groups
Distribution of patients in the New York Heart Association (NYHA) functional
classes at baseline and at 12-month follow-up in the placebo (left gold bars)
and active treatment group (right blue bars). Data are expressed as absolute
number of patients.
Serum Cytokine Levels and Metabolic Parameters at Baseline andTable 4 Serum Cytokine Levels and Metabolic Parameters at B
Variable
Placebo
Baseline 12 Months p V
TNF-alpha, pg/ml 21.7 8.3 26.1 10.9 0
IL-6, pg/ml 10.1 4.5 11.2 5.4 0
IL-1, pg/ml 459 117 574 215 0
Blood glucose, mg/dL 109 22 110 20 0
Total cholesterol, mg/dL 187 28 188 24 0
Triglycerides, mg/dL 154 76 155 69 0Data are expressed as mean SD. *p values refer to comparison of changes from baseline to 12-month
IL  interleukin; PUFA  polyunsaturated fatty acid; TNF  tumor necrosis factor.compared between groups, these changes were statistically
significant (p  0.001). In both groups, no changes were
observed in the dose of ACE-Is/ARBs and beta-blockers
between baseline and the 12-month follow-up (Table 7).
No patients underwent placement of a cardiac resynchroni-
zation therapy device during follow-up.
Discussion
The main findings of this study are that in patients with
NICM, mildly reduced functional capacity, and in stable
condition in response to maximal tolerated evidence-based
therapy, 1-year treatment with n-3 PUFAs improves pa-
rameters of LV systolic and diastolic function, as well as
functional capacity. Our data indicate that the increase in
EF is accompanied by a small but significant reduction in
diastolic and systolic dimensions and in the degree of mitral
regurgitation and is correlated with the time from diagnosis
and baseline TNF-alpha levels. The improvement of dia-
stolic function is associated with a significant decrease in
pulmonary artery systolic pressure and in left atrial dimen-
sion. From a functional standpoint, both peak VO2 and
YHA functional class appear to be favorably affected by
he treatment. These benefits are consistent with the de-
rease of the mean furosemide dose needed to maintain a
ongestion-free clinical status observed in the n-3 PUFA
roup and may account for the lower number of cardiovas-
ular hospitalizations and hospitalizations for HF recorded
uring the 12-month follow-up period in these patients
ompared with those receiving placebo.
Our evidence of an improvement in EF associated with
avorable LV remodeling is consistent with data from
onth Follow-Upne and 12-Month Follow-Up
n-3 PUFAs
p Value*Baseline 12 Months p Value
24.3 13.9 13.5 4.9 0.001 0.001
11.0 6.0 3.53 0.9 0.001 0.001
507 208 366 145 0.001 0.001
104 18 104 13 0.54 0.19
187 26 187 24 0.76 0.71
149 62 143 45 0.05 0.08
Predictors of Changes of EjectionF action in n-3 PUFA–Treat d PatientsTable 5 Predictors of Changes of EjectionFraction in n-3 PUFA–Treated Patients
Univariate
Analysis
p Value
Multivariate
Analysis
p Value
Time from diagnosis 0.001 0.001
Baseline EF 0.001 NS
Baseline TNF 0.043 0.001
Baseline IL-1 0.046 NS
Baseline IL-6 0.046 NS
EF  ejection fraction; NS  not significant; other abbreviations as in Table 4.12-Maseli
alue
.001
.001
.001
.20
.09
.87follow-up between groups.
p
t
i
s
e
t
p
i
u
(
2
E
c
t
D
t
m
s
f
t
e
c
e
d
h
o
l
a
H
i
d
s
e
i
f
f
a
s
t
m
f
m
t
a
c
f
d
877JACC Vol. 57, No. 7, 2011 Nodari et al.
February 15, 2011:870–9 PUFAs in Heart Failureexperimental studies conducted to investigate the potential
mechanisms underlying the effects of n-3 PUFAs on the
failing myocardium. In particular, in a Syrian hamster
model of idiopathic dilated cardiomyopathy, long-term
treatment with omega-3 fatty acids induced a significant
enhancement of isometric and isotonic contractile proper-
ties of isolated papillary muscle and increased actomyosin
cross-bridges number, force, and kinetics (14). In intact rats,
chronic n-3 PUFA supplementation after aortic banding
attenuated the increase in LV end-diastolic and end-systolic
volumes, the decline of the velocity of circumferential
shortening, and the reduction of LVEF, also preventing the
switch in myosin heavy chain isoform from alpha to beta
(6). Furthermore, in cardiomyopathic hamsters, n-3 PUFA
administration led to a significant improvement in the peak
rate of tension rise and peak rate of tension fall, which
indicated a faster rate of muscle contraction and relaxation,
respectively (15). These effects are likely related to the
prevention of Ca2 overload and to the decrease of sarco-
lasmatic reticulum Ca2 content (16). Taken together,
hese findings may suggest potential mechanisms underly-
ng the amelioration of diastolic function parameters ob-
erved in our active treatment group. Furthermore, the
nhanced exercise capacity recorded in the n-3 PUFA–
reated patients is consistent with an improved cardiac
erformance, which is supported by the evidence that, in
solated rat hearts, n-3 PUFAs reduce myocardial O2
consumption while sustaining cardiac output and external
work, indicating an increase in the efficiency of O2 use
nder conditions of constant HR, pre-load, and afterload
Hospitalizations During the12-Month Follow-Up PeriodTable 6 H spitalizat ns During the12-Month Follow-Up Period
Placebo n-3 PUFAs p Value
All-cause hospitalization 28 (42.4) 18 (26.9) 0.0599
Non-CV hospitalization 2 (7.1) 8 (44.4) 0.052
CV hospitalization 26 (39.4) 10 (14.9) 0.0029
HF hospitalization 20 (30.3) 4 (5.9) 0.0002
Data are expressed as n (%).
CV  cardiovascular; HF  heart failure; PUFA  polyunsaturated fatty acid.
Mean Dose of ACE-I/ARB and Beta-Blockers atTable 7 Mean Dose of ACE-I/ARB and Beta
Placebo
Drug Dose (mg)
Baseline 12
ACE-i/ARB
Enalapril 32.9 8.8 32.
Ramipril 9.1 2.0 9.
Losartan 87.5 25 87.
Candesartan 32 0 3
Beta-blocker
Carvedilol 41.9 11.7 41.
Bisoprolol 8.0 2.6 8.Data are expressed as mean SD.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin II rec17). In our study, baseline TNF-alpha levels were 1 of the
independent predictors of n-3 PUFA–related increase in
F. Active treatment significantly decreased circulating
oncentrations of TNF-alpha, IL-1, and IL-6, confirming
he experimental evidence that supplementation with EPA 
HA reduces inflammation (18), an effect possibly linked
o an increase in circulating adiponectin (19) and to the
odulation of transcription factors such as nuclear tran-
cription factor kappa B (18).
The above mechanisms may account for the overall
avorable effects on hemodynamic and functional parame-
ers observed with n-3 PUFAs and are consistent also with
pidemiological data. In particular, an analysis of a large
ohort of adults enrolled in the Cardiovascular Health Study
xplored the associations between dietary intake of fish
uring the previous year and cardiac structure, function, and
emodynamics (20). In this study, consumption of tuna or
ther broiled or baked fish was associated with a lower HR,
ower systemic vascular resistance, greater stroke volume,
nd higher E/A ratio. Additionally, the effect of n-3 PUFAs in
F may be related to an improvement of endothelial function,
ncluding a significant enhancement of endothelium-
ependent vasodilatation (21) and a reduction in the vasocon-
trictor response to angiotensin II (3). Thus, n-3 PUFAs may
xert potentially beneficial effects on multiple pathophysiolog-
cal abnormalities underlying the impairment of myocardial
unction and the progression of remodeling present in the
ailing heart. Importantly, in our study population, these
ctions appear to be independent from, and additive to, the
tandard neurohormonally and hemodynamically oriented
reatments for HF.
Among patients randomized to n-3 PUFAs, approxi-
ately 27% showed an improvement in their myocardial
unction and functional capacity parameters, and the re-
aining participants maintained their initial class. In con-
rast, in the placebo group no patients improved functionally
nd about 30% showed a decline from their baseline
ondition. Therefore, n-3 PUFAs treatment appeared to
avorably affect the progression of the disease and the
ecline of myocardial function in our population. Impor-
line and at 12-Month Follow-Upkers at Baseline and at 12-Month Follow-Up
n-3 PUFAs
Drug Dose (mg)
hs Baseline 12 Months
7 33.6 9.5 33.6 9.5
0 8.9 2.1 8.9 2.1
80.0 27.4 80.0 27.4
28.8 6.8 28.8 6.8
.5 42.0 10.6 42.0 10.6
6 9.3 1.9 8.6 2.5Base-Bloc
Mont
5 8.
1 2.
5 25
2 0
6 11
0 2.eptor blocker; PUFA  polyunsaturated fatty acid.
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PUFAs in Heart Failure February 15, 2011:870–9tantly, the time from diagnosis was inversely correlated with
the improvement of EF observed in the active treatment
group, suggesting that the beneficial effects of n-3 PUFAs
may be more evident if they are administered early in the
natural history of NICM. Furthermore, even if our inves-
tigation was not designed to explore the effects of n-3
PUFAs on prognosis, we observed a significantly lower
number of hospitalizations for cardiovascular cause and for
worsening HF, as well as a lower mean dose of furosemide,
in the active treatment group compared with the placebo
group, which is consistent with the results of the GISSI-HF
trial (2). Despite significant differences in the study design
and population characteristics, our findings may suggest
that the functional benefits observed with n-3 PUFAs may
contribute to an improvement in outcomes. Finally, n-3
PUFAs were very well tolerated, as reflected by a high
compliance, the absence of serious adverse events, and the
lack of drop-outs.
Study limitations. Our investigation was a single-center
trial with a small sample size and a limited number of
clinical events. Our evaluation of diastolic function was
performed according to the standard recommendations
published at the time of study design. Therefore, it did not
include tissue Doppler measurements, which are currently
considered an integral part of the echocardiographic assess-
ment and staging. By design, our study population included
patients with mild and moderate HF due to idiopathic
dilated cardiomyopathy, with only moderately reduced
LVEF, mildly impaired functional capacity, and an overall
good short-term prognosis. This was reflected in the ab-
sence of mortality and in a limited number of admissions
during follow-up among study participants. Therefore, our
results cannot be generalized to HF patients with a different
etiology and/or at more advanced stages of the disease.
Second, all patients were treated with maximal-tolerated
doses of evidence-based therapies, including furosemide, a
beta-blocker, an ACE-I/ARB, an aldosterone receptor
antagonist, and devices. It is not possible to infer from our
data whether the effects of n-3 PUFAs would also be
present in patients who are not receiving such treatments.
Conclusions
The results of this investigation indicate that in patients
with chronic HF and reduced LVEF due to NICM, and
minimal or no symptoms in response to evidence-based
therapy at maximal tolerated target doses, the addition of
n-3 PUFA 2 g daily for 1 year improves echocardiographic
parameters of LV systolic and diastolic function, as well as
functional capacity. These beneficial effects suggest that n-3
PUFAs may favorably affect cardiac remodeling and the
decline of myocardial function in patients with HF and may
account for the reduction in cardiovascular hospitalizations
and hospitalizations for HF observed in our study. How-
ever, whether n-3 PUFAs exert similar effects in patients
with HF caused by other etiologies, at more advancedstages, or who are not receiving evidence-based therapy
remains to be verified.
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